Who
David N. Gill
Director
Company insider
Files Form 4 as: Director, Evolus; Director, Y-mAbs Therapeutics; Director, Strongbridge Biopharma; Director, STRATA Skin Sciences; Director, Melinta Therapeutics, Inc. /new/; Director, Ocugen; President and CFO, EndoChoice Holdings; Director, Isotis.
In numbers
- Trades disclosed
- 98
- Buys
- 15
- Sells
- 7
- Bought
- $210K
- Sold
- $633K
- Companies
- 10
- Companies where not an officer
- 8
- First trade
- 10 May 2006
- Last trade
- 17 Feb 2026
- Last filed
- 19 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Feb 2026filed 19 Feb 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —45,559 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —45,559 at $0.00 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —24,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,950 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,545 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —33,450 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeutics | SEC FORM 4 Code D | $50K5,825 at $8.60 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeutics | SEC FORM 4 Code D | —25,080 | filing |
| 30 Jun 2025filed 2 Jul 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code A | —33,450 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | Y-mAbs Therapeutics | SEC FORM 4 Code A | —25,080 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,146 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —7,364 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code A | —14,545 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | Y-mAbs Therapeutics | SEC FORM 4 Code A | —3,495 at $0.00 | filing |
| 14 May 2024filed 15 May 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $85K6,718 at $12.60 | filing |
| 13 May 2024filed 15 May 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $46K3,643 at $12.72 | filing |
News
Lifecore Biomedical (NASDAQ:LFCR) vs. Evolus (NASDAQ:EOLS) Head to Head ComparisonEOLS · themarketsdaily.com · 14 Oct 2026Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaOCGN · manilatimes.net · 14 Oct 2026Ocugen (NASDAQ:OCGN) Stock: Insider Shankar Musunuri Sells 468,727 SharesOCGN · tickerreport.com · 14 Oct 2026Evolus (NASDAQ:EOLS) & Talphera (NASDAQ:TLPH) Financial ComparisonEOLS · dailypolitical.com · 13 Oct 2026Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?OCGN · prnewswire.com · 8 Oct 2026
0 headlines in the last 90 days name David N. Gill; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.